3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Breast Neoplasms
4354
Neoplasms
3056
Prostatic Neoplasms
1904
Colorectal Neoplasms
1739
Lung Neoplasms
1555
Carcinoma, Non-Small-Cell Lung
1270
Pancreatic Neoplasms
981
Leukemia, Myeloid, Acute
952
Multiple Myeloma
951
Lymphoma
912
Head and Neck Neoplasms
894
Leukemia
852
Precursor Cell Lymphoblastic Leukemia-Lymphoma
833
Neoplasm Metastasis
793
Colonic Neoplasms
785
Carcinoma, Hepatocellular
762
Ovarian Neoplasms
757
Melanoma
752
Stomach Neoplasms
742
Rectal Neoplasms
701
Brain Neoplasms
696
Lymphoma, Non-Hodgkin
663
Leukemia, Lymphocytic, Chronic, B-Cell
618
Uterine Cervical Neoplasms
607
Lymphoma, Follicular
559
Glioblastoma
541
Recurrence
539
Hodgkin Disease
532
Esophageal Neoplasms
527
Myelodysplastic Syndromes
508
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
OTHER
×
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled